Economic Burden of Checkpoint Inhibitor Immunotherapy for the Treatment of Non–Small Cell Lung Cancer in US Clinical Practice-Reference-Cited by-同舟云学术

Economic Burden of Checkpoint Inhibitor Immunotherapy for the Treatment of Non–Small Cell Lung Cancer in US Clinical Practice

Published:2020-09 Issue:9 Volume:42 Page:1682-1698.e7
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Nesline Mary K.,Knight Tyler,Colman Sam,Patel Kayshap

Funder

OmniSeq Inc

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference50 articles.

1. Speed of adoption of immune checkpoint inhibitors of programmed cell death 1 protein and comparison of patient ages in clinical practice vs pivotal clinical trials;O'Connor;JAMA Oncol,2018

2. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis;Antonia;Lancet Oncol,2019

3. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase i KEYNOTE-001 study;Garon;J Clin Oncol,2019

4. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

5. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial;Fehrenbacher;Lancet,2016

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Diagnosis-Related Groups (DRG) reform on cost homogeneity of treatment for patients with malignant tumours;Scientific Reports;2024-09-11

2. Medical costs of lung cancer by stage, histology and first-line treatment modality in the Netherlands (2012–2021);European Journal of Cancer;2024-09

3. Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy;JNCI Cancer Spectrum;2024-08-12

4. The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer;Oncology and Therapy;2024-03-19

5. Exploring the Potential of Nano Drug Delivery Systems in Non-Small Cell Lung Cancer Treatment: Recent Developments and Perspectives;Current Drug Therapy;2024-03-01